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Abstract
Background: The Mesothelioma and Radical Surgery Trial (MARS 2) aims to evaluate a surgical procedure by
comparing chemotherapy and surgery against chemotherapy alone. The pilot study for MARS 2 evaluated the
viability of recruitment. Challenges have been reported in conducting clinical research into thoracic surgical
treatments and evidence is required to improve our understanding of patient experiences of trial procedures, trial
treatments and the factors that influence participation.
Methods: This longitudinal qualitative study was nested within the MARS 2 pilot. Semi-structured telephone
interviews were conducted with 15 participants in the MARS 2 trial. Interviews were conducted post-randomisation,
post-surgery (surgery arm) and at 6 and 12 months. Altogether, 41 interviews were carried out. The data were
analysed using framework techniques.
Results: Challenges were identified regarding the volume and complexity of information given to participants, and
their understanding of clinical equipoise and randomisation. Factors influencing participation included having an
opportunity to undergo surgery, a self-assessment of their ability to cope with trial treatments, maintaining a
positive approach and altruism. Obstacles included the logistics of traveling for treatment in an unfamiliar setting.
Negative consequences of trial participation included increased uncertainty amplified by multiple care providers
and unclear transition arrangements after the trial.
Conclusions: Participants’ descriptions provided insights that have implications for care for mesothelioma trial
patients. The need for healthcare staff to be alert to the potential for misunderstanding, particularly when
presenting treatment options, was identified. Patients perceived and derived benefits from taking part in the trial
but experienced some negative consequences. These should be anticipated and managed proactively.
Trial registration: ClinicalTrials.gov, NCT02040272. Registered on 20 January 2014.
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Background
Malignant pleural mesothelioma (MPM) is a cancer of the
lining of the chest wall and lung. Its aetiology lies in asbes-
tos inhalation and exposure. Incidence is continuing to in-
crease internationally, and, with over 2500 people
diagnosed each year, the UK has the highest incidence of
mesothelioma in the world [1]. MPM mortality remains
high. In the UK, half of patients die within 8.5months of
diagnosis [1]. Chemotherapy is an established treatment
for MPM, but response rates are variable [2]. Surgical pro-
cedures for MPM may have a valuable role in future treat-
ments [3, 4]. However, access to such treatments varies
and there is a need for evidence of the effectiveness and
acceptability of surgical interventions for MPM [3–5].
Very little robust, randomised controlled trial evidence
exists for MPM surgery, with many studies being observa-
tional in nature [4, 6, 7]. As with other cancer treatments,
challenges have been reported in conducting clinical re-
search into thoracic surgical treatments, including the re-
luctance of patients to accept randomisation, a fear of
being allocated to the placebo arm, a lack of information
and support, restrictive trial regulations, achieving and
demonstrating quality control in the surgery, slow recruit-
ment processes and difficulties in presenting trial arm op-
tions neutrally [5, 8, 9]. To respond to these challenges,
evidence is required to aid our understanding of patient
experiences of surgical interventions and trials for MPM,
and of the patient motivation to participate.
The current standard treatment for MPM is chemother-
apy using the drugs cisplatin and pemetrexed. Mesothelioma
and Radical Surgery 2 (MARS 2) is a randomised trial that
seeks to compare standard chemotherapy alone with a sur-
gical intervention and standard chemotherapy. The surgical
intervention in the trial is extended pleurectomy decortica-
tion (EPD), which involves the removal of any visible meso-
thelioma, the hardened and thickened outer layer of the
surface of the lung (decortication) and the lung covering
(pleura). Depending on the extent of the disease, all or some
of the pericardium and diaphragm may also be removed.
The pilot study for MARS 2 evaluated the potential to
recruit to the trial. The primary endpoint was the ability
to randomise 50 patients within the first 24 months or
the ability to recruit 25 patients in any 6-month period.
The pilot stage of MARS 2 is now complete, and MARS
2 has rolled out to a full trial.
The focus of this paper is the qualitative sub-study
(QSS) within MARS 2. The QSS was embedded in the
pilot stage of MARS 2 and aimed to generate insights
into the patient experience of recruitment, consent and
randomisation along with the influences and motivations
underlying their decisions. The QSS also explored the
experience of the MARS 2 treatment interventions and
associated care and support needs. This paper presents
the findings regarding trial procedures and participation.
Methods
Study design
This was an applied health research study that adopted a
longitudinal qualitative methodological approach. It was
nested within the clinical trial feasibility pilot study for
MARS 2.
Study population
Participants were patients who were taking part in the
MARS 2 pilot study, which employed a two-stage un-
blinded two-arm parallel-design randomised trial. Eli-
gible patients had histological confirmation of MPM
such that the disease was confined to one hemi-thorax
based on a computerised tomography (CT) assessment.
Patients were excluded if they were unable to consent or
be randomised, if the disease was not resectable, if they
had co-morbidities (respiratory, cardiac, kidney or liver)
or if they had a European Cooperative Oncology Group
performance status of 2 or more. After two cycles of
standard-of-care chemotherapy (platinum and peme-
trexed), those whose disease had not progressed beyond
surgically resectable limits were randomised to either
EPD or no surgery. All patients were then scheduled to
receive a further four cycles of standard-of-care chemo-
therapy. Two surgical centres in England performed the
EPD, one in Leicester and the other in Sheffield. A con-
venience sample of MARS 2 participants were sequen-
tially recruited for the QSS post-randomisation.
Data collection and analysis
All patients who consented to participate in the
MARS 2 pilot study were informed that they may also
be invited to take part in the QSS, which was evaluat-
ing patient experience. Following randomisation, a
member of the QSS research team contacted pilot
study participants by telephone to ask if they wished
to consider also taking part in the QSS study. Those
who agreed to consider participation were given in-
formation about the QSS and an opportunity to ask
questions during this phone call. Following the tele-
phone conversation, a QSS-specific study participation
information sheet and QSS consent form were sent in
the post along with a stamped addressed envelope.
The first interview with each participant was carried
out after the return of the written consent form and
confirmation of consent.
Semi-structured telephone interviews were con-
ducted. Participants receiving surgery and chemother-
apy were scheduled to be interviewed four times.
Interview 1 was post-randomisation but prior to sur-
gery. Subsequent interviews were within 4 weeks after
surgery and at 6 and 12 months after the initial inter-
view. Participants receiving chemotherapy alone were
interviewed on three occasions. The first was post-
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randomisation and then at 6 and 12 months following
the first interview.
Interviews were carried out by two researchers (CW
and KL) between August 2015 and March 2017. Neither
researcher was involved in the wider MARS 2 clinical
trial. The interviews ranged in duration from 8 to 45
min and were digitally recorded and transcribed verba-
tim. A topic guide was developed to keep the interview
focused on the participant’s experience of the MARS 2
trial and interventions (Fig. 1). However, the discussion
remained flexible to allow for participants to raise issues
not anticipated or identified a priori. Previous transcripts
for each participant were read prior to their subsequent
interviews to enable further discussion of individual
themes. The guide was reviewed at a midway point in
the data collection, when the team reflected on the
emerging findings and additional prompts were added
(Fig. 1).
The data were analysed using the framework approach
[10]. The transcripts were checked for accuracy and after
initial familiarisation with the data, a preliminary the-
matic framework was developed from the data (CW and
KL). The transcripts were independently analysed (AT
and BT). The themes were then discussed across the re-
search team and the framework was revised in the light
of agreement. The data were then coded and sorted by
theme and subtheme to facilitate further analysis and
discussion. This process of analysis and discussion was
then repeated until a consensus was reached regarding
the final thematic framework and findings. This analytic
process was carried out at regular points during the data
collection and analysis to ensure the emerging findings
influenced the data collection and the development of
the study findings.
Results
In total, 16 people were invited to join the QSS. One de-
clined participation as they felt unable to take on add-
itional commitments so that 15 were recruited. Nine
participants were receiving chemotherapy and surgery
and six receiving chemotherapy alone. Eight participants
were from the Leicester centre and seven from the Shef-
field centre; 14 were male, age range 59 to 82 (mean
70.13). Out of the potential 54 interviews, 41 were car-
ried out. Seven participants completed all their sched-
uled interviews. Table 1 is a summary of the interviews
completed for each participant.
The analysis identified four main themes, which pro-
vide insight into participants’ experiences of the trial
procedures and trial participation:
1) learning about the trial
2) deciding to join the trial
3) experience of trial procedures
4) feeling supported during the trial
Fig. 1 Key questions from the MARS 2 QSS interview topic guide
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Learning about the trial
The context of trial information provision
Participants’ descriptions of the events leading up to
the trial consultation identified that it took place in a
context of new, unexpected and concerning experi-
ences regarding their mesothelioma diagnosis. These
included the onset of worrying symptoms, hospital
visits, diagnostic tests and investigations, and in most
cases, the drainage of litres of fluid from the lung.
The majority had received their mesothelioma diagno-
sis only a few weeks prior to the trial consultation
and all had been told that they had a rare incurable
cancer associated with a poor prognosis. In addition,
they had also learnt that their cancer was an occupational
disease caused by exposure to a substance that they may
have worked with many years previously, which had legal
and financial ramifications. Many described how challen-
ging it had been to assimilate and understand the informa-
tion and experiences they had gone through before
finding out about MARS 2.
Well, you know, it's in a different field that you've not
been experienced in before, and for somebody to turn
around and say that you've got this condition and your
time is limited, it is very daunting. (Participant 6)
There were variations in the diagnostic pathways and
information provided to each participant prior to their
trial consultation but most shared the elements sum-
marised here. One notable difference was the informa-
tion given at diagnosis about treatment options. Some
had been told at the time about the potential for trial
treatments, while others had been informed that there
was no treatment available:
[The doctor] said it's inoperable and there was
nothing as sure as that, because we were amazed
when eventually we came out of hospital and made
another appointment to see [a doctor] back at our
own local hospital and it was him who suggested
the MARS 2 trial. (Participant 9)
Information about treatment options: understanding
clinical equipoise
All participants reported feeling informed during re-
cruitment about the treatment options in the trial. How-
ever, there was evidence that some had inferred from
their trial consultation that surgery could be the pre-
ferred treatment from the perspective of the doctor pro-
viding the explanation.
He explained to me that … if it was him personally
that had mesothelioma, if surgery was available as
well as chemotherapy he would probably go down
that, if he had the ability to affect the outcome he
would hope for it and probably would want it.
(Participant 13)
Well, I think he said the surgery's proven to be a bit
more … you know, whatever the symptoms are, a bit
more controllable or something. (Participant 2)
Table 1 Summary of interviews










1 Surgery Yes Yes No (died) NA
2 Surgery Yes Yes Yes No (no reply to contact)
3 Surgery Yes Yes Yes No (died)
4 Surgery Yes Yes Yes Yes
5 Chemotherapy Yes NA Yes Yes
6 Surgery Yes No (died) NA NA
7 Surgery Yes Yes No (no reply to contact) No (died)
8 Surgery Yes Yes No (withdrew) No (died)
9 Chemotherapy Yes NA Yes Yes
10 Chemotherapy Yes NA Yes No (died)
11 Surgery Yes Yes Yes Yes
12 Chemotherapy Yes NA Yes Yes
13 Chemotherapy Yes NA Yes Yes
14 Surgery Yes Yes Yes No (withdrew)
15 Chemotherapy Yes NA Yes Yes
NA not applicable
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However, many also described being told that the trial
was being carried out because the optimal treatment for
mesothelioma was not known. This included some who
recalled that the doctor had inferred a preference.
It has been explained to me in words of one syllable …
that there is no evidence that adding radical surgery
will make a massive difference. … To be fair to them,
they said we just do not know and that is the reason
why we are conducting the trial. (Participant 13)
In some interviews, it was not possible to identify
whether clinical equipoise had been conveyed during the
consultation. This was particularly the case when partici-
pants described how they felt the surgeon had endorsed
surgery when explaining the intention and potential ben-
efits of this treatment. Participants’ descriptions may
have reflected inferences they made about the presenta-
tion of information by the surgeons or it may have been
that the surgeon was not in equipoise.
He said, well, if you had the surgery … he said two
things. he said, it will extend your life and make it
easier so if you can get that, that’s fine. (Participant 1)
He said, I wouldn't be doing this operation if I didn't
think it was going to give you a better time of life. He
didn't say what length of life he said better time of life.
(Participant 6)
He said, even if I take everything I can see, he says,
it will still not stop. It will only slow it, you know,
he says, but it will give you a bit more time.
(Participant 9)
Deciding to join the MARS 2 trial
Influences on the decision to participate
Reasons given for deciding to participate in the MARS 2
pilot trial were multi-faceted. Where participants were
keen to receive surgery, trial participation was a way to
achieve this. There was also a perception from some that
they might receive enhanced care and support by being
on a trial. In many cases, a factor that influenced their
decision-making was their own self-assessment of their
ability to cope physically with treatment, particularly
surgery.
A lot of people my age have got all sorts wrong with
them. I don’t take any medication at all, so it’s got to
make a difference. I think when you go to have any
sort of operation … then your health, of course, is an
important factor in that. (Participant 1)
Perceived psychological benefits also appeared to influ-
ence MARS 2 trial participation. Many spoke of the im-
portance of taking a positive approach to their illness
and treatment, and trial participation supported this by
providing access to what they felt to be new or up-to-
date treatments. In addition, altruism, through improv-
ing future treatment, was described as a motivating
factor by most participants.
What I wanted from MARS was that... It has given me
some hope, because in the beginning they were … a
little bit, “Oh you've only got so long” and all the rest
of it, you know what I mean? And I was thinking, “Oh
… bugger this for a game of soldiers!” That ... apart
from giving other people a chance, that it would also
give me a chance, if you understand. (Participant 10)
Potential obstacles to participation
While the participants in this study had all decided to
take part in the trial, some had considered not doing so
due to the logistics associated with receiving treatment
some distance from home. This was both for surgery
and chemotherapy, as some had to pass local chemo-
therapy providers to reach the participating treatment
centre. Organising travel and hotel accommodation were
challenges for some, and information regarding this was
not always readily available.
And when I saw [the doctor] he said, “Oh, we can help
with your expenses and stuff like that.” I went, “Right,
okay.” And then I’ve asked a few people … and they
don’t really know nothing about it. (Participant 3)
These logistical issues continued to be a source of
concern for some throughout the trial treatments.
Having these recognised and acted on by the health-
care team was viewed positively where it had been
experienced. An example was scheduling appoint-
ments to co-ordinate with train times when there was
a long distance to travel.
I came down to see [the surgeon], and when I spoke to
his secretary on the phone, I said, “Look, I need to have
an appointment sort of late morning because I’ve got to
get the train down,” and that was no bother. She said,
“No, that’s fine.” And then my wife and I had a nice
train ride down there. That was okay. (Participant 1)
Experience of trial procedures
Understanding randomisation
There was evidence of variation in the accuracy of par-
ticipants’ understanding of trial procedures, including
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randomisation, which is summarised in Table 2. Many
used phrases such as “a 50:50 chance” or “could go
either way”, which indicates that they were aware that
they could get either treatment at randomisation.
However, six QSS participants did not fully under-
stand randomisation and the way in which decisions
about the treatment they would be receiving were
made. Three thought a doctor made the decision
based on what was best for the patient. Two thought
a computer was given information that helped to se-
lect the most appropriate treatment.
They put all the results … into a computer and
then the computer spits out a name. … “I don’t
want her. Yes, we’ll have him.” ... Presumably
there’s criteria that it has to meet and obviously,
because I had responded to the treatment and
that’s why I got picked for the surgery.
(Participant 11)
Treatment preferences and randomisation
Participants were asked if they had a treatment prefer-
ence prior to randomisation. Four declared that they had
no preference while seven stated they would have pre-
ferred surgery. Two different explanations were given
for this. The first was a belief that surgery was inher-
ently a more effective treatment as it physically re-
moved the cancer. The second was a desire to receive
all the treatment that was available.
I felt that if I can use this term “the full loaf” if
you like, the whole loaf was really a process of
receiving both aspects—chemotherapy and the
radical surgery.
(Participant 13)
Four participants declared a preference for chemother-
apy, which seemed to be based on concerns about the
physical challenges associated with surgery.
I still consider myself quite fit and I thought to myself
maybe if I had that op it could flatten me like and put
me out for months and months. So, I wasn’t too upset,
put it that way. … If [surgery] had been offered to me,
I would have taken it, but secretly I was glad that it
wasn’t. (Participant 5)
Table 2 Understanding of randomisation along with treatment preferences and outcomes
Participant number Treatment preference Randomisation
outcome
Understanding of randomisation
1 Surgery Surgery Good
2 Surgery Surgery Good
3 Surgery Surgery Not clear. Participant initially described that he
could have received either treatment but later in the interview stated
that he had been randomised to surgery as the chemotherapy
was not working for him.
4 Surgery Surgery Good
5 Chemotherapy Chemotherapy Good
6 No preference Surgery Poor. Patient thought that doctors make
the decision and that the trial is comparing
types of surgery
7 No preference Surgery Not clear from discussion
8 No preference Surgery Poor. Patient thought that doctors
make the decision
9 Surgery Chemotherapy Good
10 Surgery Chemotherapy Good
11 Chemotherapy Surgery Poor. Patient thought that a computer makes
the decision by assessing their individual situation
from the information provided
12 Chemotherapy Chemotherapy Poor. Patient thought that a computer makes the
decision by assessing their individual situation from
the information provided
13 Surgery Chemotherapy Good
14 Chemotherapy Surgery Poor. Patient thought that doctors make the decision
and that the trial is comparing types of surgery
15 No preference Chemotherapy Good
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For some, the waiting time between consenting to trial
participation and the point of randomisation was a
period of sustained anxiety.
Interviewer: “Were you aware that you might not have
got into that treatment arm”?
The reply was:
Oh, yes, of course I was, all the time. I was wanting
the operation from the beginning and I knew that it
was random on a computer and that’s what
panicked me. … I don’t know whether chemotherapy
works or the other type works, but what I’m saying
is I knew my best way would be an operation. … I
was worried I might not get the randomisation and
get the operation. (Participant 4)
Treatment preferences and randomisation outcomes
Five participants did not get their preferred treatment
choice (Table 2). Those who did not get surgery had
concerns that chemotherapy might not be as effective as
surgery. They also described their disappointment in
contrast to their earlier optimism of getting through to
randomisation, which meant they had been told their
mesothelioma was operable and then informed they
were not going to have the operation.
I sort of got my hopes built up. ... I had a scan,
blood tests and then the breathing tests and
everything, and the surgeon said that I would be an
ideal candidate for it. So, I was sort of upbeat for
that … and then it came up with the chemo. …
Then, to be perfectly honest with you, I was a little
bit, “Oh”. You know what I mean? It was like
someone putting a pin in a balloon. Not with it
going bang but deflated. (Participant 10)
The participants who had wanted chemotherapy but
had been randomised to surgery responded with sto-
icism or managed to change their perspective on it
[I] sort of wished I hadn’t got to go through it, but you
take what is given and offered.
(Participant 11)
Very hesitant. I was still very dubious. … But I think
it’s the best way for me to go actually. … I got my head
round it and with [my wife] being registered disabled, I
look after her as well and I think it’ll gee me on to get
things done so I can carry on looking after her.
(Participant 14)
Feeling supported during the trial
Overall, the care provided during the MARS 2 pilot
study recruitment and treatment delivery was de-
scribed in a positive light. This positive perspective
was underpinned by an appreciation that treatment
was available and was reinforced by positive feelings
towards the National Health Service in general. Other
factors relating to care were also praised, such as the
behaviours and attitudes of staff towards them as
individuals.
I can't fault the hospital or anything like that. … The
nurses and the surgeon and everything like that was
good. The people in the CT scan and the X-ray depart-
ment were brilliant. So I can't, you know, I can't fault
any of that. (Participant 10)
All participants reported feeling informed about the
mesothelioma treatment options in the trial, felt they
had been given opportunities to discuss them and said
that they had not felt under pressure to participate.
Many praised the depth and quality of the verbal infor-
mation that they had received about the trial. Being
shown scans and computer images were described as
particularly helpful in supporting their understanding of
their diagnosis and the surgical procedures, as was the
amount of time that staff had taken to give them infor-
mation and explanations. However, some found the lan-
guage and detail provided in the written information
confusing. For example,
We tend to get bombarded with paperwork and
booklets, and I’ve tried to read them all and some of it
makes sense and some of it’s way over my head. …
Sometimes understanding the expressions that they use
and the descriptions of various things. … Sometimes it
does seem an awful lot of stuff to take in. … Not all of
it will apply to all people. It’s sometimes a bit
confusing sorting out the exact very important bits.
(Participant 4)
Receiving information from more than one team
member using a different approach or language was de-
scribed as one way to make the trial more accessible.
I went first to see [the surgeon] and there were a
nurse there. [The nurse] gave me more literature,
but she told me in our term of speaking exactly
what it was. So it were down to her … who broke it
into my language for me, to understand fully what
was going on.
(Participant 14)
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Participants indicated that information regarding the
trial was in plentiful supply. However, some gaps in
the information and support regarding the trial pro-
cesses and procedures were described in the inter-
views. These included:
 Clear plans regarding the scheduling of
chemotherapy and surgery post-randomisation: For
some, there was a period when they did not know
what the plans were. Others recalled being given
very little notice, for example, being informed of the
date a few days before admission.
 Post-trial plans including what will happen after
the trial, who will be responsible for their
ongoing treatment, who to contact for advice,
and future treatments that might be needed
or available.
Uncertainty and trial participation
There was evidence of fragmented care between the
different treatment and service providers, for example,
the chemotherapy centre not being aware of the po-
tential date for the resumption of treatment post-
operatively. This created a sense of uncertainty and
added to participants’ anxiety.
We had to phone up. And she didn't know nothing
about the trial. I said, “Oh, do you know if I'm
coming?” “You know more than me,” she said, “I
haven't heard nothing yet.” Anyway, I think because
it's a new trial, maybe they're sorting things out
and that.
(Participant 2)
The end of treatment and the trial were also times
that triggered uncertainty among participants. Some
found these trial transitions difficult because they
were losing contact with healthcare staff with whom
they had built a relationship. This appeared to be ex-
acerbated by the absence of a clear plan for ongoing
care and support during the post-treatment recovery
phase as well as ongoing disease surveillance as they
continued to live with mesothelioma.
I'm not saying that they're not bothered about you.
… It just seems they pass you on from one to
another and you don't get the same, like, personal
attention, sort of thing. It’s not as though they’re
doing anything personal, but you don't get the same
feedback, the information. They seem to know more
about you if you're seeing somebody all the time.
(Participant 9)
Participant: “There were times when there was a long
gap with apparently nothing happening. … It was a long
time with no clinics. … It seemed a long time, in fact.”
Interviewer: “Would you have preferred someone to
have contacted you?”
Participant: “That may well have eased things knowing
that you were not forgotten.” (Participant 12)
Discussion
This longitudinal QSS has generated information about
the experiences of patients going through a multi-step
clinical trial for mesothelioma. It reveals their motiva-
tions to take part and their experiences of trial proce-
dures. It provides insight into why recruitment to
previous thoracic surgical trials may have been challen-
ging [7–9].
The study identified considerable challenges in pre-
senting information to patients considering trial partici-
pation due to the timing, volume and complexity of
information. From the perspective of some participants,
an understanding of equipoise was not achieved. With-
out direct observation of trial communication in clinics,
it is not possible to know if what was reported by partic-
ipants was actually said or was a misunderstanding by
the patient. Either way, this finding highlights that staff
involved in recruitment need to be aware of the poten-
tial for their words to be misinterpreted by patients. This
is particularly important, as some participants were sub-
sequently randomised to receiving a treatment that they
felt was perceived to be less effective by healthcare staff.
The main MARS 2 trial, which is now in progress, con-
tains an embedded Quintet Recruitment Intervention
[11], one aspect of which is to audio-record consulta-
tions when the MARS 2 study is explained and to inter-
view patients afterwards, so that this issue can be
explored further and addressed.
Participants’ understanding of randomisation was also
found to be variable. Previous studies have observed that
the term “randomisation” and the concept of random al-
location is often unknown to patients prior to being of-
fered trial participation [12]. In addition, patients
sometimes assume that individual characteristics, or the
decision of a doctor, are the reason for their allocation
to a particular treatment arm [12, 13]. The findings from
the MARS 2 pilot QSS also raise the possibility that trial
procedures may contribute to difficulties with under-
standing complex concepts such as randomisation. In
MARS 2, prior to randomisation, the surgeon reviewed a
CT scan to determine whether the participant was still
eligible for surgery. The data indicate this could have
been misinterpreted as the doctor deciding whether sur-
gery was the right treatment for them. Working with pa-
tients to co-produce information that communicates
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trial procedures and processes effectively may be a useful
approach to meeting this challenge. A co-production ap-
proach could help to identify language and phrases that
have less scope for misunderstanding.
Most participants of the QSS held preferences for a
particular treatment. The time leading up to randomisa-
tion was experienced as a period of anxious uncertainty,
as they waited to find out if they were to receive their
preferred intervention. Participants’ descriptions of their
experiences suggest that consultations regarding ran-
domisation outcomes should be recognised as moments
when significant information is given. When the alloca-
tion differs from the patient’s preferred outcome, it may
be beneficial to approach it as breaking bad news and
managed in the same way.
Agreement to enter the trial was associated with add-
itional pressures for study participants. Acknowledging
the negative implications of trial participation in initial
discussions may help to prepare participants for this.
While a degree of uncertainty is to be expected, our study
revealed that it was exacerbated when there was poor co-
ordination or communication between treatment pro-
viders. Uncertainty was common when patients moved to
post-treatment recovery and surveillance. Indeed, some
accounts of this period provided a stark comparison be-
tween the intensity of support at recruitment compared to
when patients were exiting the trial. The potential for pa-
tients to have negative experiences when leaving a trial
has been identified in previous research, with some pa-
tients describing how they felt abandoned or “set loose” as
they lose the support that accompanies trial participation
[14]. Employing a care coordinator or navigator may pro-
vide a solution to these problems. Care navigators track
the patient’s progress along the trial and treatment path-
way, keep in touch with the patient and facilitate commu-
nication between the different service providers, which
has led to positive patient outcomes in other cancer set-
tings [15]. This may be a useful role to consider in clinical
trials care. In addition, an exit consultation in which fu-
ture treatment and surveillance plans are outlined and
which implements elements of the Macmillan Cancer
Support Recovery Package [16] may help to ease uncer-
tainty after a clinical trial and bridge the gaps between sec-
ondary and primary care.
The main strength of our study is the use of longitudinal
qualitative data collection methods to explore the reasons
behind participants’ decisions to participate in a clinical
trial and their understanding and experience of trial pro-
cedures. The sample size is relatively small, but the longi-
tudinal methods provided opportunities to revisit themes
and subjects arising from earlier interviews and capture
participants’ experience during the trial, from early in-
volvement when the focus is on the trial procedures, ran-
domisation and the decision to participate, to later stages
as participants leave the trial. While sampling in qualita-
tive methods is not intended to be representative, partici-
pants were from a wide geographical area. The findings
are limited to those who were mesothelioma patients and
who agreed to participate in the MARS 2 clinical trial;
therefore, saturation may not have been achieved. How-
ever, an in-depth understanding of patients’ experience
across time was generated. The experiences of those who
declined participation pre- or post-randomisation would
provide additional and potentially different insights into
the subjects explored.
Conclusion
The study provides insights into the challenges facing pa-
tients in absorbing and understanding the volume of com-
plex information associated with trial participation. It
highlights the importance of healthcare staff being alert to
the potential for misunderstanding, particularly when pre-
senting treatment options. Patients perceived and derived
benefits from taking part in the trial, but negative conse-
quences, such as uncertainty regarding treatment plans
and transition arrangements at trial completion, should be
anticipated and managed proactively.
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